The latest trial over claims that the discontinued heartburn drug Zantac causes cancer ended with a hung jury on Wednesday, ...

Pfizer aims to achieve significant savings, targeting at least $4 billion in net cost savings by the end of 2024. This disciplined approach not only supports the company's financial health but ...

The pure-play consumer health company ... its share price since GSK spun it off in 2022. There was also an overhang of shares to hold back the stock price. But now, Pfizer has cut its stake ...

Nevertheless, Haleon is a great stock for the current environment we’re in. The resilience of its brands is fueling investors’ interest in HLN — as are fears about a slowing U.S. economy and ...

The results from the phase I/II study equal or even exceed the immune responses generated by Pfizer’s PFE Prevnar 20, which is the current standard of care in ... ago period. GSK plc GSK has ...

NYSE:PRGO) Perrigo Appoints Industry Veteran, Charles Atkinson, as Executive Vice President, General Counsel and Secretary ...

Benefits for patients and the public Can provide opportunities to make a difference, shape future care, give something back to the health ... GSK and the Patient-Centered Outcomes Research Institute, ...

Junaid Bajwa, MBBS, is chief medical scientist at Microsoft and a physician in the UK’s National Health Service. In September 2024, he will join Flagship Pioneering as a senior partner. Post ...

To counter new forms of the virus, FDA approved updated vaccines from both Pfizer and Moderna last week. These new vaccines specifically target the KP.2 strain, a descendant of the Omicron variant.

GSK, Pfizer PFE.N, Sanofi SASY.PA and Boehringer Ingelheim are asking the court to overturn an order by a lower court judge allowing plaintiffs in the lawsuits to offer expert testimony ...